Please Wait

Applying Filters...

Drug Product Composition: D00451

D00451

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

58 API Suppliers, 26 USDMF, 14 CEP/COS, 4 JDMF, 17 EU WC, 6 KDMF, 18 NDC API, 25 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

6 Drugs in Development

6 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

394 FDF Dossiers, 100 FDA Orange Book, 212 Europe, 33 Canada, 15 Australia, 19 South Africa, 15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML), INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 100MG BASE, TABLET;ORAL - EQ 25MG BASE, TABLET;ORAL - EQ 50MG BASE, SYSTEM;IONTOPHORESIS - EQ 6.5MG BASE/4HR, POWDER;NASAL - EQ 11MG BASE, SPRAY;NASAL - 20MG/SPRAY, SPRAY;NASAL - 5MG/SPRAY, TABLET;ORAL - 500MG;EQ 85MG BASE, TABLET;ORAL - 60MG;EQ 10MG BASE, INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML), INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Actylis, 1 Finar

EXCIPIENTS BY APPLICATIONS

1 Parenteral, 1 Topical

DIGITAL CONTENT

35 News #PharmaBuzz

35 News #PharmaBuzz

GLOBAL SALES INFORMATION

31 US Medicaid Prescriptions, 178 Regulatory FDF Prices, 8 Annual Reports

MARKET PLACE

13 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

49 US Patents, 10 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM

3 EDQM

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 206099 / DOSAGE - POWDER;NASAL - EQ 11MG BASE

Drug Product Composition: D00451

D00451

D00451

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

58 API Suppliers

26 USDMF

14 CEP/COS

4 JDMF

17 EU WC

6 KDMF

18 NDC API

25 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

6 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

394 FDF Dossiers

100 FDA Orange Book

212 Europe

33 Canada

15 Australia

19 South Africa

15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 100MG BASE

TABLET;ORAL - EQ 25MG BASE

TABLET;ORAL - EQ 50MG BASE

SYSTEM;IONTOPHORESIS - EQ 6.5MG BASE/4HR

POWDER;NASAL - EQ 11MG BASE

SPRAY;NASAL - 20MG/SPRAY

SPRAY;NASAL - 5MG/SPRAY

TABLET;ORAL - 500MG;EQ 85MG BASE

TABLET;ORAL - 60MG;EQ 10MG BASE

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Actylis

1 Finar

EXCIPIENTS BY APPLICATIONS

1 Parenteral

1 Topical

DIGITAL CONTENT

35 News #PharmaBuzz

GLOBAL SALES INFORMATION

31 US Medicaid Prescriptions

178 Regulatory FDF Prices

8 Annual Reports

MARKET PLACE

13 APIs

1 FDF Dossiers

PATENTS & EXCLUSIVITIES

49 US Patents

10 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM

Filters

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons